CN104987409A - Lead-IgG chelate as well as preparation method and application thereof - Google Patents

Lead-IgG chelate as well as preparation method and application thereof Download PDF

Info

Publication number
CN104987409A
CN104987409A CN201510412319.XA CN201510412319A CN104987409A CN 104987409 A CN104987409 A CN 104987409A CN 201510412319 A CN201510412319 A CN 201510412319A CN 104987409 A CN104987409 A CN 104987409A
Authority
CN
China
Prior art keywords
igg
lead
inner complex
sample
chromatography column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510412319.XA
Other languages
Chinese (zh)
Other versions
CN104987409B (en
Inventor
张积仁
阳帆
董欣敏
吴婧
蔡睿
孙遥
赵乙木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Jinhai Health Technology Co ltd
Original Assignee
Shanghai Baihao Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Baihao Biotechnology Co Ltd filed Critical Shanghai Baihao Biotechnology Co Ltd
Priority to CN201510412319.XA priority Critical patent/CN104987409B/en
Publication of CN104987409A publication Critical patent/CN104987409A/en
Application granted granted Critical
Publication of CN104987409B publication Critical patent/CN104987409B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a lead-IgG chelate as well as a preparation method and application thereof. The lead-IgG chelate is formed by chelating lead ions with IgG through sulfydryl or/and cysteine residues. According to the invention, a qualitative and quantitative detection method of the lead-IgG chelate is established for favorably quantitatively detecting the application of the lead-IgG chelate to the evaluation of the lead pollution degree of one region. By quantitatively detecting the lead-IgG chelates in serums of people in one region, the condition that people in the region are polluted by lead can be indirectly reflected, and further the lead pollution degree of the region is indirectly reflected. According to the quantitative detection method for the lead-IgG chelate, established by the invention, the accuracy is greatly improved, and the detection repeatability is greatly improved.

Description

A kind of lead-IgG inner complex and its preparation method and application
Technical field
The present invention relates to detection field, more particularly, relate to a kind of lead-IgG inner complex and its preparation method and application.
Background technology
IgG, primarily of the plasmocyte synthesis in spleen, lymphoglandula and secretion, exists with monomeric form.In ontogenetic process, the age of body synthesis IgG will be later than IgM, and within 3rd month, start synthesis after birth, 3 ~ 5 years old close to grownup's level.IgG is antibody component main in serum, accounts for 75% of serum total Ig.IgG is uniquely by the Ig of placenta, plays an important role in natural passive immunity.In addition IgG also has opsonophagocytosis, ADCC and in conjunction with effects such as SPA.Due to IgG These characteristics, IgG plays a part main in immunity of organism protection, and most of antibacterial, antiviral, t antibody all belongs to IgG antibody-like.Apply and can carry out artificial immunity to the immune puerpera such as measles, hepatitis A or normal people third kind or placental globulin, prevent corresponding communicable disease while suburb can be had.
Plumbous content in vivo exceedes certain level will cause to health the infringement being difficult to recover, it can lead fume, lead dust and various oxide form are taken in body by human body through respiratory tract and digestive tube, by the Competition with calcium ion, oxidative damage, the mechanism such as apoptosis, cause based on nerve, digestion, the general of hemopoietic system obstacle, gradual, persistence non-reversibility disease, and its harm also may be genetic to the next generation.Anaemia is one of saturnine early symptom, and lead can suppress the activity of many enzymes in protoheme building-up process.Lead poisoning can cause vasospasm, angina abdominis, retinal arterioles spasm and hypertension, often causes tiny arteriosclerosis.Plumbous renal impairment often shows as the pathology such as interstitial nephritis or atrophic ephritis, and reabsorption function reduction is early stage symptom.Effects of Lead Exposure also may affect reproductive function, and the probability of the plumbous women's generation Infertility of contact, miscarriage and stillborn foetus increases, and by with it placental metastasis to fetus.Per os lead poisoning person liver is one of main damaged organ, hepatomegaly can be caused to present jaundice, even liver cirrhosis or hepatic necrosis, and hepatic injury may be that in liver, arteriolospasm causes caused by local asphyxia.Lead causes Porphyrin Metabolism obstacle, suppresses containing sulfydryl enzyme, interference vegetative nerve.
Research finds to send out plumbous, and error at measurment is large, and tooth is plumbous, bone is plumbous and organize lead to draw materials not easily, and lead in urine mainly reflects plumbous excretion situation.China's " children's Lead-poisoning and lead poisoning prevention guide " regulation in 2006, the examination of children blood lead levels can adopt peripheral blood or venous blood, but diagnosis must adopt venous blood.But the content affecting the protein binding lead of immunity of organism sphaeroprotein has no precedent detection.
More than comprehensive, about lead poisoning, the particularly evaluation of chronic lead poisoning, only by detecting blood lead content, the circulation lead content in indirect reaction human body, the plumbous degree of injury for body function cannot be assessed further, and along with the develop rapidly of science and technology, plumbous also day by day tight with the relation of human body, thus finding one can become more and more important from the evaluation of body function angle lead poisoning, the particularly chronic lead poisoning evaluation method for the degree of damage of body.
Summary of the invention
For the problem that Lead contamination is serious, the object of the present invention is to provide a kind of lead-IgG inner complex and preparation method thereof, and set up the qualitative and quantitative analysis method of lead-IgG inner complex, so that detection by quantitative lead-IgG inner complex is in the application of an evaluation Pb pollution level.Indirectly can reflect the situation of this regional crowd by Lead contamination by detection by quantitative one regional crowd's Lead in Serum-IgG inner complex, thus indirectly reflect this Pb pollution level.
The technical solution adopted for the present invention to solve the technical problems is: provide a kind of lead-IgG inner complex, lead ion and IgG by sulfydryl or/and cysteine residues chelating forms.
The present invention also provides a kind of preparation method of above-mentioned lead-IgG inner complex, comprises the following steps:
A) chelatropic reaction of lead and IgG: add lead ion and carry out chelatropic reaction in the IgG in people source, obtain reaction soln;
B) extraction of purifying lead-IgG inner complex: adopt immune-affinity chromatography, removes unreacted IgG and unnecessary lead ion in reaction soln, obtains plumbous-IgG inner complex.
Wherein, step B described in external synthesis method) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgG inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgG specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgG and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgG inner complex.
Wherein, the preparation method of above-mentioned lead-IgG inner complex, also comprises step C): to the qualification of lead-IgG inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgG inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
The present invention also provides the application of a kind of lead-IgG inner complex described above in preparation human body in the reagent of lead-IgG inner complex or test kit.
The present invention also provides a kind of test kit at least comprising lead-IgG inner complex described above product in contrast.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the albumen can catching IgG or the material of catching metallic lead.
The present invention also provides a kind of method of detection by quantitative lead-IgG inner complex, with the above-mentioned lead-IgG inner complex product in contrast of known content, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgG inner complex and enzyme linked immunological combined techniques, purification lead-IgG inner complex and atomic absorption spectrum combined techniques, purification lead-IgG inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
Implement lead-IgG inner complex of the present invention and its preparation method and application, there is following beneficial effect:
1. the present invention's external synthesis lead-IgG inner complex first;
2. the present invention proposes lead-IgG inner complex first and can be used for preparing application in the reagent or test kit detecting lead-IgG inner complex in blood sample.
3. the present invention establishes the method for qualitative and quantitative detection of lead-IgG inner complex, so that detection by quantitative lead-IgG inner complex is in the application of an evaluation Pb pollution level.Indirectly can reflect the situation of this regional crowd by Lead contamination by detection by quantitative one regional crowd's Lead in Serum-IgG inner complex, thus indirectly reflect this Pb pollution level.Its accuracy of lead-IgG inner complex quantitative detecting method that the present invention sets up improves greatly, and the repeatability of detection is greatly enhanced.
Accompanying drawing explanation
Fig. 1 is the non denatured electrophoretic band figure of lead-IgG inner complex of the present invention;
Fig. 2 is the fluorometric analysis figure of the synchrotron radiation X line electrophoretic band of lead-IgG inner complex of the present invention;
Wherein, in Fig. 1, M is Marker, and 5 is lead-IgG inner complex; In Fig. 2, X-coordinate is protein band position, and ordinate zou is lead metal energy in this protein band.
Embodiment
Below, in conjunction with embodiment, the present invention is described further:
Unless otherwise indicated, the laboratory operating procedures related to is the step of this area routine in the present invention, and agents useful for same, material are as cited by following, and the reagent being this area conventional not enumerating out in the present invention maybe can be obtained by commercial mode:
Extracting reagent is PEG solution, borate buffer solution etc. (adopting PEG method);
Glue bed medium is the one in sepharose, polyacrylamide gel;
In the present invention described can with the filler of IgG specific binding, for surface is with the silica gel of albumen or the resin that can catch IgG;
The albumen (anti-igg antibody) catching IgG in the present invention, include but not limited to rabbit Anti-IgG H & L, its brand is Abcam, model is ab6715;
In the present invention can with the filler of plumbous specific binding, for surface is with silica gel or the resin that can catch plumbous material;
Plumbous material can be caught in the present invention, include but not limited to mouse-anti Pb mAb, buy from Ba Ao moral biotech company (BioWorld Inc), article No. be AP7019;
Enzyme labelled antibody is the one in the antibody containing the enzyme labelling such as horseradish peroxidase, alkaline phosphatase;
Substrate is methyl diphenyl amine (TMB) solution;
Washings is for containing KH 2pO 40.2mg/ml, Na 2hPO 412H 2the pH of O 2.90mg/ml, NaCl8.0mg/ml, KCl 0.2mg/ml, 0.5%Tween-20 is the 0.15M PBS solution of 7.4;
Confining liquid is 1%-5% bovine serum albumin or skim-milk;
Dilution buffer is for containing 1.5mg/mL Na 2cO 3, 2.93mg/ml NaHCO 3pH be 9.6 0.05M phosphate buffered saline buffer;
Enzyme labelled antibody is HRP enzyme labelled antibody;
Stop buffer is: by the 2M H of 21.7ml 2sO 4be settled to the ddH of 200ml 2in O;
Elutriant be containing the PH of 1-2mg/ml papoid be 8.0 0.1mol/L Tris-HCL damping fluid;
Souring agent is nitric acid;
Sample-loading buffer is for containing 1M Tris-HCl (pH 6.8) 15.5mL, 1% tetrabromophenol sulfonphthalein 2.5mL, ddH 2the Sample buffer (5X) of O7mL, glycine 25mL;
Electrophoretic buffer be containing Tris 3mg/ml, glycine 14.4mg/ml PH be the ddH of 6.8 2o solution.
The invention provides a kind of lead-IgG inner complex, lead ion and IgG by sulfydryl or/and cysteine residues chelating forms.
The present invention also provides a kind of preparation method of lead-IgG inner complex, comprises the following steps:
A) the plumbous chelatropic reaction with IgG: add lead ion in the IgG in people source or the IgG that recombinates according to biological method and carry out chelatropic reaction, obtain reaction soln;
B) extraction of purifying lead-IgG inner complex: adopt immune-affinity chromatography, remove unreacted IgG and unnecessary lead ion in reaction soln, obtain plumbous-IgG inner complex, concrete steps are as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgG inner complex is redissolved
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgG specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgG and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgG inner complex;
C) to the qualification of lead-IgG inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgG inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
The present invention also provides a kind of test kit at least comprising lead-IgG inner complex described above product in contrast.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the material that the albumen can catching IgG maybe can catch metallic lead.
In the present invention, the test kit that can realize the object of the invention can be listed following several, but is not limited to this.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: containing catching the coating buffer of albumen of IgG, confining liquid, washings, material, enzyme labelled antibody, substrate, stop buffer, dilution buffer, sample-loading buffer, positive control, negative control etc. as two anti-caught lead.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: the coating buffer, confining liquid, washings, elutriant, sample-loading buffer, positive control, negative control etc. that contain the albumen can catching IgG.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: the coating buffer, confining liquid, washings, elutriant, sample-loading buffer, souring agent, hydrogen peroxide, standard substance, negative control etc. that contain the albumen can catching IgG.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: as extracting reagent, redissolution liquid in purification whole blood needed for IgG, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, sample-loading buffer, positive control, negative control etc. that can catch plumbous material.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: as extracting reagent, redissolution liquid, sample-loading buffer, positive control, negative control etc. in purification whole blood needed for IgG.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: extract reagent, sample-loading buffer, redissolution liquid, souring agent, hydrogen peroxide, positive control, negative control etc. needed for IgG as in purification whole blood.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: contain liquid needed for protein band leaded on the coating buffer of the albumen can catching IgG, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, positive control, negative control etc. that can catch plumbous material.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: as extracting liquid, positive control, negative control etc. needed for protein band leaded on reagent, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed in purification whole blood needed for IgG.
Detect a test kit for lead-IgG inner complex in blood sample, comprising: as extracting liquid, souring agent, hydrogen peroxide, positive control, negative control etc. needed for protein band leaded on reagent, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed in purification whole blood needed for IgG.
In above-mentioned several test kit, described positive control is standard substance, is namely chelated with the IgG inner complex of heavy metal lead or is chelated with the BSA inner complex of heavy metal lead; Described negative control is dilution buffer.
Mentioned reagent box is for detecting the IgG of chelating lead, to improve the accuracy of detection, repeated, and makes it to be promoted in clinical.
The present invention also provides a kind of method of detection by quantitative lead-IgG inner complex, with the above-mentioned lead-IgG inner complex product in contrast of known content, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgG inner complex and enzyme linked immunological combined techniques, purification lead-IgG inner complex and atomic absorption spectrum combined techniques, purification lead-IgG inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.In the present invention, following several with having of detecting that the method for plumbous chelating type immunocomplex can list, but be not limited to following several.
Wherein, the reagent adopted in the method for above-mentioned detection by quantitative lead-IgG inner complex is as follows:
method one:euzymelinked immunosorbent assay (ELISA) (ELISA method) detects lead-IgG inner complex, detects in accordance with the following steps:
1) material of IgG can be caught, as human IgG antibody is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 50000-400000 times, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) material can catching lead is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add with dilution buffer dilution and plumbous material can be caught or can react with lead the anti-pb Ab forming immune complex, 37 DEG C of effect 1-2 hour, make the metallic lead on anti-pb Ab and IgG react;
6) enzyme conjugates incubation: remove anti-antibody lead, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/ml, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: drip stop buffer to each micropore;
9) wavelength 405nm is got, after adding stop buffer, elisa plate is placed in OD value microplate reader reading respectively measuring samples and standard substance, by standard substance drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by staining conditions) of measuring samples.
The method utilizes ELISA principle, specific IgG in whole blood can be extracted, the IgG upper part extracted is chelated with heavy metal lead, and lead on this part IgG can catch by the specific antibody of anti-lead, afterwards can again by horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase is caught (this antibody nonrecognition coating protein), the antibody of catching is under the effect of developer and stop buffer, OD value can be read under instrument, and the IgG not containing chelated mineral lead, then can not catch by the specific antibody of anti-lead, also can not with horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase caught, and also not containing metallic lead (negative control group result is negative) in agents useful for same, thus when read OD value result is shown as the positive, the i.e. provable metallic lead detecting chelating on IgG.
method two:enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect lead-IgG inner complex and detect in accordance with the following steps:
1) material of IgG can be caught, as human IgG antibody is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 50000-400000 times, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rpm, centrifugally discard precipitation;
3) close: remove coating buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, with elution 1-3 hour.
6) detect: sample from ELISA micropore, detect the lead of chelating on IgG in Atomic Absorption Spectroscopy AAS, and drawing standard curve, read respective value;
In conjunction with atomic absorption spectrum (AAS) principle on the basis that this embodiment utilizes ELISA principle, Atomic Absorption Spectroscopy AAS is utilized to detect the lead of chelating on IgG, owing to only containing IgG in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable metallic lead detecting chelating on IgG.
method three:enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect lead-IgG inner complex and detect in accordance with the following steps:
1) material of IgG can be caught, as human IgG antibody is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 50000-400000 times, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, with elution 1-3 hour.
6) acidifying: in step 5) in solution in add souring agent acidifying carried out to solution, sealing is spent the night, thorough acidifying;
7) detect: add hydrogen peroxide, and acid is caught up with in heating, and from ELISA agent plate wash-out solution in sample, under icp ms, detect chelating in the lead of IgG, and drawing standard curve, read respective value.
The method is on the basis utilizing ELISA principle, in conjunction with sense coupled plasma mass spectrometry (ICP-MS) principle, the lead of chelating on IgG is detected with icp ms, owing to only containing IgG in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable metallic lead detecting chelating on IgG.
method four:purification lead-IgG inner complex and enzyme linked immunological combined techniques (method of purification+ELISA method) detect lead-IgG inner complex, detect in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to adopt whole blood extraction method to be redissolved by the purification of blood IgG out, obtain the redissolution liquid of IgG;
2) anti-pb Ab is coated on solid phase carrier: dilute anti-pb Ab to 500000-4000000 doubly by dilution buffer, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) measuring samples is added, and incubation: sample from the redissolution liquid of the IgG extracted, make measuring samples; Standard substance are made with the lead-IgG inner complex of known content; Dilute corresponding multiple by dilution buffer, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) enzyme conjugates incubation: the redissolution liquid removing IgG, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/ml, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
6) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
7) termination reaction: drip stop buffer to each micropore;
8) wavelength 405nm is got, after adding stop buffer, elisa plate is placed in OD value microplate reader reading respectively measuring samples and standard substance, by drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by staining conditions) of measuring samples.
method five:purification lead-IgG inner complex and atomic absorption spectrum combined techniques (method of purification+AAS method) detect lead-IgG inner complex in blood sample, detect in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgG out from whole blood extraction method, obtain the redissolution liquid of IgG;
2) detect: from step 1) redissolution liquid in sample, detect the lead of chelating on IgG in Atomic Absorption Spectroscopy AAS, and drawing standard curve, read respective value.
method six:purification lead-IgG inner complex and inductivity coupled plasma mass spectrometry combined techniques (method of purification+ICP-MS method) detect lead-IgG inner complex, detect in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgG out from whole blood extraction method, obtain the redissolution liquid of IgG;
2) acidifying: from step 1) redissolution liquid in sample, add souring agent (as nitric acid) in the solution and carry out acidifying to solution, sealing is spent the night, thorough acidifying;
3) detect: add hydrogen peroxide, and acid is caught up with in heating, and sample from corresponding solution, under icp ms, detect the lead of chelating on IgG, and drawing standard curve, read respective value.
method seven:electrophoresis and euzymelinked immunosorbent assay (ELISA) (electrophoretic method-ELISA method) detect lead-IgG inner complex, detect in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgG out from whole blood extraction method, obtain the redissolution liquid of IgG;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, conventionally prepare corresponding glue bed;
3) application of sample: get step 1) in redissolution liquid 8 μ L add 2 μ L sample-loading buffers, mixing, of short duration centrifugal; (noticing that step can not be boiled herein)
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize ELISA principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgG of this method detection chelating lead, molecular weight and content etc. can also be utilized.
method eight:electrophoresis and atomic absorption spectrometry (electrophoretic method-AAS method) detect lead-IgG inner complex, detect in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgG out from whole blood extraction method, obtain the redissolution liquid of IgG;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, prepare glue bed;
3) application of sample: from step 1) redissolution liquid in sample, add sample-loading buffer, and mix, then application of sample is in sample cell;
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize AAS principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgG of this method detection chelating lead, molecular weight and content etc. can also be utilized.
method nine:inductivity coupled plasma mass spectrometry combined techniques (electrophoretic method-ICP-MS method) detects lead-IgG inner complex, detects in accordance with the following steps:
1) from whole blood, IgG is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgG out from whole blood extraction method, obtain the redissolution liquid of IgG;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, prepare corresponding glue bed according to corresponding requirements;
3) application of sample: from step 1) redissolution liquid in sample, add sample-loading buffer, and mix, then application of sample is in sample cell;
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize ICP-MS principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgG of this method detection chelating lead, molecular weight and content etc. can also be utilized.
IgG in method seven to nine can by multiple Methods For Purification out (such as ultracentrifugation, HPLC, gel-filtration chromatography, gel electrophoresis, ELISA method etc.), the IgG purified out is redissolved, obtain the redissolution liquid of IgG, get a certain amount of IgG, utilize electric charge shifting principle, carry out electrophoresis (electrophoresis, EP), can according to molecular weight on gel slab (different media can be adopted as required), the difference such as iso-electric point runs out of different bands, find out and be rich in plumbous respective strap, protein in gel is redissolved, namely the content of relevant IgG can be detected at a particular wavelength, also ELISA can be utilized, AAS, the principles such as ICP-MS detect the lead content of chelating on IgG, owing to only containing IgG in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, the i.e. provable metallic lead detecting chelating on IgG.
embodiment 1: the preparation method of lead-IgG inner complex, comprises the following steps:
A) chelatropic reaction of lead and IgG: add lead ion and carry out chelatropic reaction in the IgG in people source, obtain reaction soln;
Preparation of reagents:
1) borate buffer solution (0.01M): take 0.31g boric acid and be dissolved in 400ml ultrapure water, regulates pH to 9.0 with the NaOH of 0.1M, is settled to 500mL.
2) IgG solution: take 4.0mgIgG and be dissolved in 4.0mL 0.01M pH9.0 borate buffer solution, dissolving of fully vibrating, is mixed with the protein solution of 1.0mg/mL;
3) 5mmol/L EDTA+200mmol/LNaHCO 3solution: take EDTA2H 2o 1.86g, NaHCO 316.8g is dissolved in 900mL ultrapure water, adjusts pH to 8.0 be settled to 1000ml, autoclaving, room temperature preservation with 1.0M NaOH;
4) ITCBE (buying from Japanese colleague's chemistry institute, article No. M030)
5) dialysis tubing (molecular weight cut-off 14000) (Bioshop Inc)
Preparation process is specially:
1) process of dialysis tubing: 5mmol/L EDTA+200mmol/L NaHCO dialysis tubing being put into 500ml (according to the convertible consumption of beaker volume) volume 3in solution, boil 10min; Tipping EDTA/NaHCO 3liquid, with ultrapure water rinsing gently, then boils 10min with 500ml 5mmol/L EDTA; Discard boiling liquid, thoroughly with ultrapure water cleaning, add a large amount of ultrapure water immersion dialysis tubings 4 DEG C and spend the night.During use, put on one's gloves, take out dialysis tubing, with a large amount of its surfaces externally and internallies of ultrapure water cleaning down;
2) getting 2.0mg ITCBE is dissolved in 2ml DMSO;
3) getting 4.0mg IgG to be dissolved in 4.0ml borate buffer solution in (0.01M pH9.0);
4) liquid slowly step 2 prepared adds in IgG solution, and dropping limit, limit is shaken, and in 25 DEG C, acts on 24h in the shaking table of 100r/min, then to dialyse 24h with dialysis tubing, removes the ITCBE be not combined with IgG;
5) by the liquid 1mol/L HCl adjust ph to 7.0 of dialysis gained, then slowly drip 80 μ l 1mmol/L lead ion solution gradually, dropping limit, limit vibrates, in order to avoid lead ion makes protein denaturation precipitate;
6) by the solution that added at 25 DEG C, react 2h in the shaking table of 100r/min, carry out dialysis 24h with the dialysis tubing handled well;
7) liquid after dialysis is preserved in-20 DEG C of packing.
B) extraction of purifying lead-IgG inner complex: adopt immune-affinity chromatography, remove unreacted IgG and unnecessary lead ion in reaction soln, obtain plumbous-IgG inner complex, concrete steps are as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgG inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgG specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgG and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgG inner complex;
C) to the qualification of lead-IgG inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using sepharose as medium;
(2) application of sample: get step B) in the lead-IgG inner complex that obtains of 8 μ L extraction purification, add 2 μ L sample-loading buffers, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, add electrophoretic buffer and carry out electrophoresis; In electrophoresis process, electric current is 22mA constant current, and envrionment temperature is 4 degree; Electrophoresis is stopped when moving to bottom glue to tetrabromophenol sulfonphthalein;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of AAS method whether contain plumbous and detect plumbous content.
D) detected result
(1) electrophoresis result:
Wherein, Fig. 1 is the non denatured electrophoretic band figure of lead-IgG inner complex of the present invention.
(2) Synchrotron Radiation X-Ray Fluorescence Anal ysis:
In protein band, the SRXRF of micronutrient levels analyzes and " synchrotron radiation bunch completes at the 4W1 of Beijing electron positron collider (BEPC).In storage ring, beam current energy is 2.2GeV, beam intensity 100mA.Sample transfer table (TSA200 type, Beijing stand upright Han Guang company) can move up to change launching spot position along X, Y two-dimensional square under computer-controlled step motor drives, and moving step length is 0.0025mm.The X-ray gone out from electromagnetic radiation is detected by Si (Li) detector (PGT Inc.LS 30143-DS), probe is mutually vertical with incident SR line copline, apart from sample irradiation point 20mm, signal obtains with PGT MCA (MCA4000) and exports.By the monochromatic synchrotron radiation light excited sample of 11.5keV, launching spot (1mmx3mm) position is regulated to make it to be in band one end, in the minute of 300s, hot spot is always along band evenly slowly movement, and at the end of counting, hot spot moves on to this band the other end.A spectrum is got along the every 1mm in electrophoresis direction.Adopt AX IL software data processing, and with deriving from air and the Ar fignal center of content constant carries out normalization to other element peak, to offset the impact that beam intensity change produces signal power.Measure the fluorescence Spectra of the dry glued membrane of quantitative criterion at identical conditions in the same way.
Fig. 2 is the fluorometric analysis figure of the synchrotron radiation X line electrophoretic band of the electrophoresis strip of lead-IgG inner complex of the present invention, and in figure, X-coordinate is protein band position, and ordinate zou is lead metal energy (content) value in this protein band.
(3) lead content in the lead-IgG inner complex adopting graphite furnace atomic absorption spectrometry (AAS) rough determination the present embodiment to obtain, its content is 484.151 μ g/L.
the determination of the testing conditions of the method for a kind of detection by quantitative lead of the present invention-IgG inner complex:
1. the determination of the optimum diluting multiple of complement proteins best effort concentration and blood plasma
Step is as follows:
(1) will resist igGab dilution buffer is diluted according to following mass volume ratio (extent of dilution) 1:50000,1:100000,1:200000,1:400000, adds in elisa plate micropore, will resist igGab is coated on solid phase carrier, and each concentration bag is by three rows, and 4 DEG C are spent the night 18 hours;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) measuring samples and dilution buffer are diluted according to following mass volume ratio (extent of dilution) 1:10,1:20,1:40, add in micropore, resisting according to above-mentioned bag quilt igGab concentration, resisting of same concentration igGab adds different extent of dilution blood plasma respectively, and 37 DEG C act on 1 hour;
(4) measuring samples is removed, and wash with washings, after washing completes, add anti-pb Ab, anti-pb Ab and dilution buffer are diluted according to following mass volume ratio (extent of dilution) 1:500000,1:1000000,1:2000000,1:4000000, and according to each identical anti-igg Ab, serum-dilution concentration, the anti-pb Ab of different concns respectively adds 2 holes, 37 DEG C act on 1 hour, the metallic lead on anti-pb Ab and IgG are reacted;
(5) enzyme labelled antibody selects the suitableeest working concentration, i.e. 2ng/ml, removes anti-pb antibody, and wash with washings, after washing completes, add with dilution buffer dilution HRP enzyme labelled antibody, 37 DEG C act on 1 hour, HRP enzyme labelled antibody and lead-IgG inner complex are reacted;
(6) remove enzyme labelled antibody, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dripped to each micropore with the speed identical with adding substrate solution and order;
(8) get wavelength 405nm, after adding stop buffer, elisa plate is placed in microplate reader and reads each hole OD value respectively.According to each hole OD value numerical value, select anti-igg Ab, the best effort concentration of anti-pb-Ab and the optimum diluting multiple of blood plasma.
Simultaneously using made reference substance as positive control in test, IgG antibody+closed+pb is selected to resist+enzyme mark+substrate (namely do not add and detect sample) as negative control 1, IgG antibody+close+blood plasma+enzyme mark+substrate (namely not adding pb to resist) as negative control 2, IgG antibody+close+enzyme mark+substrate (namely do not add detect sample and pb resist) is as negative control 3, IgG antibody+close+blood plasma+pb is anti-+ and substrate (i.e. not enzyme-added mark) is as negative control 4, close+blood plasma+pb is anti-+ and enzyme mark+substrate (namely not adding IgG antibody) is as blank 1, only add substrate and PBS as blank 2, detected result is in Table 1-2.
The determination of table 1: anti-igg Ab and pb antibody best effort concentration and diluted plasma multiple
Table 2:ELISA positive control and negative control ELISA detected result
By table 1-2 data presentation, when we can find out that the extent of dilution as human IgG antibody is 1:100000, whole blood extent of dilution be the anti-extent of dilution of 1:20, pb is 1:1000000, OD value is maximum, although OD value is less than 0.8, but the negative control group OD value corresponding to it is all less than 0.1, and the positive controls corresponding to it, OD value is greater than 0.8, so select the concentration corresponding to this value, as best effort concentration, (namely human IgG antibody's concentration is 1:100000, whole blood extent of dilution is the anti-weaker concn of 1:20, pb is 1:1000000).
2.ELISA elutriant best effort concentration and time are determined
Step is as follows: human IgG antibody is diluted to 100000 times (mass volume ratios) by dilution buffer by (1), adds in elisa plate micropore, 37 DEG C of water-baths 3 hours, stores refrigerator;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) remove confining liquid, and wash with washings, after washing completes, add the HRP enzyme labelled antibody with dilution buffer dilution, 37 DEG C act on 2 hours, itself and human IgG antibody are reacted;
(4) prepare elutriant: papoid pH 8.0,0.1mol/L Tris-HCI buffer is become 1-2mg/ml, then add 1mmol/L dithiothreitol (DTT) (DTT) 37 DEG C and hatch 30min;
(5) enzyme labelled antibody is removed, by dilution buffer, elutriant is diluted, make the Papain enzyme concn in elutriant: enzyme labelled antibody concentration ratio=1:80,1:40,1:20,1:10,1:5, wherein, each concentration does 3 multiple holes, is positioned over wash-out 1h, 2h, 3h at 37 DEG C of temperature respectively;
(6) remove elutriant, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dripped to each micropore with the speed identical with adding substrate solution and order;
(8) get 405nm wavelength, after adding stop buffer, be placed in by elisa plate in microplate reader and read often group OD value respectively, by comparing with PBS damping fluid group, compare optimal concentration and the elution time of elutriant, concrete outcome is see table 3.
Table 3:ELISA elutriant best effort concentration and elution time are determined
1:5 1:10 1:20 1:40 1:80
1h 0.281 0.168 0.081 0.114 0.469
2h 0.250 0.115 0.050 0.183 0.438
3h 0.225 0.106 0.100 0.196 0.441
From table 4, we can find, during ratio=the 1:20 of the concentration of the papoid in elutriant with the concentration of enzyme labelled antibody, during the concentration 100ng/ml of i.e. papoid, each group of OD value is all lower than other several groups, this concentration elution effect optimum (reach maximum by the human IgG antibody that ELISA hole wall combines-enzyme mark mixture wash-out degree, thus OD value is minimum) is described; And no matter action time is 1h, 2h, 3h, the change of each group OD value is all little, as seen along with the prolongation of time, enzyme activity weakens gradually, when enzyme concn is constant, extend digestion time can not improve digestibility, so in this experiment the action time of elutriant be that 1-3h all can.
application Example 1
Get and adopt ELISA method to detect lead-IgG inner complex in 100 parts of sample blood plasma, detect according to following steps: euzymelinked immunosorbent assay (ELISA) (ELISA method) detects lead-IgG inner complex, detect in accordance with the following steps:
1) anti-igg Ab is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 100000 times, add in elisa plate micropore, 37 DEG C of water-baths 1 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 20 times, add in micropore, 37 DEG C act on 1 hour;
5) material can catching lead is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add and dilute 1000000 times by dilution buffer, 37 DEG C act on 1 hour, the metallic lead on anti-pb Ab and IgG are reacted;
6) enzyme conjugates incubation: remove anti-antibody lead, and wash with washings, after washing completes, adds the HRP enzyme labelled antibody with dilution buffer dilution, and 37 DEG C act on 1 hour, itself and enzyme labelled antibody are reacted;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: drip stop buffer to each micropore;
9) get wavelength 405nm, after adding stop buffer, elisa plate is placed in the OD value (also can not use microplate reader, directly carry out qualitative detection by staining conditions) microplate reader reading respectively measuring samples and standard substance, detected result is as shown in table 4.
The ELISA detected result of lead-IgG inner complex in table 4:100 part blood sample
application Example 2
Employing enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect the lead-IgG inner complex in 100 points of sample blood samples, detect in accordance with the following steps:
1) material of IgG can be caught, as anti-igg antibody (anti-igg Ab) is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 100000 times, add in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get whole blood from the recycle system, make measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to 20 times with dilution buffer dilution measuring samples, add in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and washing with washings, after washing completes, the elutriant that to add with the concentration of papoid be 100ng/ml, wash-out 3 hours;
6) detect: sample from ELISA micropore, detect the lead of chelating on IgG in Atomic Absorption Spectroscopy AAS, detected value is as shown in table 5.
The AAS detected result of lead-IgG inner complex in table 5:100 part blood sample
Numbering 1 2 3 4 5 6 7 8 9 10
μg/L 2.33 3.064 1.484 3.319 3.438 2.581 2.404 0.839 2.959 2.744
Numbering 11 12 13 14 15 16 17 18 19 20
μg/L 2.998 2.74 2.644 0.781 2.412 2.970 2.654 2.49 1.037 2.551
Numbering 21 22 23 24 25 26 27 28 29 30
μg/L 2.739 3.007 2.720 2.429 0.844 2.670 2.619 2.753 2.702 1.017
Numbering 31 32 33 34 35 36 37 38 39 40
μg/L 2.348 2.398 2.753 2.320 2.595 0.783 2.914 2.735 2.364 2.413
Numbering 41 42 43 44 45 46 47 48 49 50
μg/L 1.092 2.716 2.844 2.808 2.466 1.909 3.416 2.765 2.964 2.849
Numbering 51 52 53 54 55 56 57 58 59 60
μg/L 2.541 2.96 0.915 2.579 2.482 0.856 3.033 2.958 3.068 2.735
Numbering 61 62 63 64 65 66 67 68 69 70
μg/L 3.061 2.485 2.308 2.848 2.578 3.851 3.066 2.809 2.824 2.451
Numbering 71 72 73 74 75 76 77 78 79 80
μg/L 2.675 2.682 2.463 1.866 2.3 2.834 2.438 2.827 1.859 2.791
Numbering 81 82 83 84 85 86 87 88 89 90
μg/L 2.558 2.802 3.059 2.924 0.881 2.961 2.83 3.090 2.302 1.030
Numbering 91 92 93 94 95 96 97 98 99 100
μg/L 2.867 2.958 2.335 3.001 3.043 0.923 3.003 2.520 1.956 2.915
application Example 3
Employing enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect the lead-IgG chelate content in 100 points of sample blood samples, detect in accordance with the following steps:
1) material of IgG can be caught, as anti-igg antibody (anti-igg Ab) is coated on solid phase carrier: by dilution buffer dilution anti-igg Ab to 100000 times, add in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get 100 parts of standard blood samples as measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgG inner complex of known content; Be diluted to 20 times with dilution buffer dilution measuring samples, add in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and washing with washings, after washing completes, the elutriant that to add with the concentration of papoid be 100ng/ml, wash-out 3 hours;
6) acidifying: in step 5) in solution in add nitric acid acidifying carried out to solution, sealing is spent the night, thorough acidifying;
7) detect: add hydrogen peroxide, and acid is caught up with in heating, and sample from corresponding solution, under icp ms, detect chelating in the lead of IgG, detected value is as shown in table 6.
The ICP-MS detected result of table 6 100 parts of sample blood sample lead-IgG inner complexs
Numbering 1 2 3 4 5 6 7 8 9 10
μg/L 2.511 2.699 2.867 2.663 2.764 2.939 2.579 1.120 2.63 2.953
Numbering 11 12 13 14 15 16 17 18 19 20
μg/L 2.786 2.887 1.048 2.557 1.958 2.773 2.813 2.36 2.651 2.768
Numbering 21 22 23 24 25 26 27 28 29 30
μg/L 2.673 2.921 2.727 0.714 2.349 2.623 2.639 2.305 2.468 0.945
Numbering 31 32 33 34 35 36 37 38 39 40
μg/L 2.926 2.969 0.666 2.874 2.769 2.859 3.071 2.519 2.638 2.551
Numbering 41 42 43 44 45 46 47 48 49 50
μg/L 2.929 2.342 3.850 3.681 3.045 2.595 2.617 2.402 2.541 0.956
Numbering 51 52 53 54 55 56 57 58 59 60
μg/L 2.439 2.488 2.954 3.069 1.650 2.448 2.839 2.564 2.999 2.442
Numbering 61 62 63 64 65 66 67 68 69 70
μg/L 1.136 2.784 2.354 2.332 2.738 2.49 2.525 2.96 2.728 2.581
Numbering 71 72 73 74 75 76 77 78 79 80
μg/L 3.516 3.096 2.533 0.900 3.065 1.951 2.447 2.366 2.769 2.632
Numbering 81 82 83 84 85 86 87 88 89 90
μg/L 3.09 2.933 3.014 3.024 0.900 2.93 2.462 2.734 2.421 1.454
Numbering 91 92 93 94 95 96 97 98 99 100
μg/L 2.332 2.385 2.768 2.601 2.829 0.779 2.339 2.658 0.984 3.839
To one skilled in the art, according to technical scheme described above and design, other various corresponding change and deformation can be made, and all these change and deformation all should belong within the protection domain of the claims in the present invention.

Claims (8)

1. a lead-IgG inner complex, is characterized in that, lead ion and IgG by sulfydryl or/and cysteine residues chelating forms.
2. a preparation method for lead-IgG inner complex as claimed in claim 1, is characterized in that, comprise the following steps:
A) the plumbous chelatropic reaction with IgG: people source IgG or the IgG that recombinates according to biological method in add lead ion and carry out chelatropic reaction, obtain reaction soln;
B) extraction of purifying lead-IgG inner complex: adopt immune-affinity chromatography, removes unreacted IgG and unnecessary lead ion in reaction soln, obtains plumbous-IgG inner complex.
3. preparation method according to claim 2, is characterized in that,
Described step B) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgG inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgG specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgG and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH 2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgG inner complex.
4. the preparation method of lead-IgG inner complex according to claim 2, is characterized in that, also comprise step C): to the qualification of lead-IgG inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgG inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
5. the application of lead-IgG inner complex as claimed in claim 1 in the reagent or test kit preparing to detect lead-IgG inner complex in blood sample.
6. one kind at least comprises the test kit of lead-IgG inner complex as claimed in claim 1 as standard substance.
7. test kit according to claim 6, is characterized in that, also comprises coating buffer, and this coating buffer contains the material that the albumen can catching IgG maybe can catch metallic lead.
8. the method for a detection by quantitative lead-IgG inner complex, it is characterized in that, using the lead-IgG inner complex according to claim 1 of known content as standard substance, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgG inner complex and enzyme linked immunological combined techniques, purification lead-IgG inner complex and atomic absorption spectrum combined techniques, purification lead-IgG inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
CN201510412319.XA 2015-07-14 2015-07-14 lead-IgG chelate as well as preparation method and application thereof Expired - Fee Related CN104987409B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510412319.XA CN104987409B (en) 2015-07-14 2015-07-14 lead-IgG chelate as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510412319.XA CN104987409B (en) 2015-07-14 2015-07-14 lead-IgG chelate as well as preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN104987409A true CN104987409A (en) 2015-10-21
CN104987409B CN104987409B (en) 2018-01-05

Family

ID=54299324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510412319.XA Expired - Fee Related CN104987409B (en) 2015-07-14 2015-07-14 lead-IgG chelate as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN104987409B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108663528A (en) * 2018-06-12 2018-10-16 广东腾湃医疗股份有限公司 A kind of excellent effect lead chelating type immune complex and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022490A1 (en) * 1993-03-29 1994-10-13 Immunomedics, Inc. Conjugates of proteins and bifunctional ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022490A1 (en) * 1993-03-29 1994-10-13 Immunomedics, Inc. Conjugates of proteins and bifunctional ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108663528A (en) * 2018-06-12 2018-10-16 广东腾湃医疗股份有限公司 A kind of excellent effect lead chelating type immune complex and preparation method thereof

Also Published As

Publication number Publication date
CN104987409B (en) 2018-01-05

Similar Documents

Publication Publication Date Title
CN105137059B (en) Mercury chelating immune complex and preparation method and application thereof
CN104987409A (en) Lead-IgG chelate as well as preparation method and application thereof
CN104987412A (en) Arsenic-IgE chelate as well as preparation method and application thereof
CN105021548B (en) Arsenic-fibrinogen chelate as well as preparation method and application thereof
CN105153299A (en) lead-IgM chelate as well as preparation method and application thereof
CN104961824A (en) Lead and high-density lipoprotein chelate as well as preparation method and application thereof
CN104987411A (en) Cadmium-IgA chelate as well as preparation method and application thereof
CN104987400A (en) Mercury-hemoglobin chelate as well as preparation method and application thereof
CN104987407A (en) Cadmium-IgG chelate as well as preparation method and application thereof
CN104987410A (en) Lead-IgE chelate as well as preparation method and application thereof
CN104987404A (en) Nickel-IgG chelate as well as preparation method and application thereof
CN105044004B (en) Mercury-IgM chelate as well as preparation method and application thereof
CN104987414A (en) Nickel-IgM chelate as well as preparation method and application thereof
CN105115914B (en) Cadmium-low density lipoprotein chelate as well as preparation method and application thereof
CN105044006B (en) Mercury-IgG chelate and preparation method and application thereof
CN105001321A (en) Mercury-fibrinogen chelate and preparation method and application thereof
CN105001310B (en) Chromium-chelated immune complex and preparation method and application thereof
CN105021554B (en) arsenic-IgM chelate as well as preparation method and application thereof
CN105017430B (en) Nickel chelate immune complex and preparation method and application thereof
CN105004684A (en) Nickel-IgE chelate as well as preparation method and application thereof
CN104987405A (en) Arsenic-IgG chelate as well as preparation method and application thereof
CN104987415A (en) Chromium-IgM chelate as well as preparation method and application thereof
CN105037537A (en) lead-IgA chelate as well as preparation method and application thereof
CN105044007B (en) cadmium-IgM chelate as well as preparation method and application thereof
CN104987413A (en) Arsenic-IgA chelate as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210420

Address after: Room 3787, 3rd floor, No.22 GUANGTANG West Road, Tianhe District, Guangzhou, Guangdong 510630

Patentee after: Guangzhou Jinhai Health Technology Co.,Ltd.

Address before: 200000, Shanghai, Pudong New Area, China (Shanghai) free trade zone, new Jinqiao Road, No. 13, building 27, 2 floor

Patentee before: SHANGHAI BAIHAO BIOTECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180105

Termination date: 20210714

CF01 Termination of patent right due to non-payment of annual fee